Michael P. Manos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael P. Manos has a total of 199 co-authors. Here are the top co-authors by number of shared publications:
- Anita Giobbie-Hurder
Dana-Farber Cancer Institute, Boston, MA
62 shared publications - Frank Stephen Hodi
Dana-Farber Cancer Institute 6 , Boston, Massachusetts
62 shared publications - Scott Rodig
Harvard Medical School, Boston, Massachusetts
51 shared publications - Kathleen L. Pfaff
Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA
49 shared publications - Joanna Baginska
Center for Immuno-oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
47 shared publications - Jason L. Weirather
Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
39 shared publications
Latest Publications
- Open Access
Genomic classification and immune profiling define mucosal melanoma
Mucosal melanoma is a rare, lethal melanoma subtype with distinct genetics and limited benefit from immunotherapy. To define features associated with mucosal melanoma clinical outcomes, we assembled a large, multimodally profiled cohort spanning primary and metastatic disease. Compared with cutaneous melanoma, primary mucosal melanoma showed greater genomic heterogeneity, ploidy and aneuploidy, and a more dedifferentiated, proliferative transcriptional state. Analysis of genomic sequencing of 339 patients with mucosal melanoma identified four mutually exclusive genomic subtypes: CDK4/MDM2/CCND1, SF3B1-mutated, TP53/ATRX, and mucosal melanoma Triple WT, associated with distinct anatomic sites but similar outcomes. In the tumor microenvironment, we observed reduced T cell infiltration and increased CD163 + tumor-associated macrophages in mucosal melanoma relative to cutaneous melanoma. In matched longitudinal samples, CD163 + tumor-associated macrophages increased with disease progression and immunotherapy resistance. CD163 + tumor-associated macrophages engaged non-regulatory T cells through GAL9–TIM-3 interactions, nominating TIM-3 blockade as a therapeutic strategy for mucosal melanoma. These findings define the distinct aggressive biology of mucosal melanoma and highlight potential therapeutic targets and mechanisms of immune resistance.
Open AccessGenomic classification and immune profiling define mucosal melanoma
Mucosal melanoma is a rare, lethal melanoma subtype with distinct genetics and limited benefit from immunotherapy. To define features associated with mucosal melanoma clinical outcomes, we assembled a large, multimodally profiled cohort spanning primary and metastatic disease. Compared with cutaneous melanoma, primary mucosal melanoma showed greater genomic heterogeneity, ploidy and aneuploidy, and a more dedifferentiated, proliferative transcriptional state. Analysis of genomic sequencing of 339 patients with mucosal melanoma identified four mutually exclusive genomic subtypes: CDK4/MDM2/CCND1, SF3B1-mutated, TP53/ATRX, and mucosal melanoma Triple WT, associated with distinct anatomic sites but similar outcomes. In the tumor microenvironment, we observed reduced T cell infiltration and increased CD163 + tumor-associated macrophages in mucosal melanoma relative to cutaneous melanoma. In matched longitudinal samples, CD163 + tumor-associated macrophages increased with disease progression and immunotherapy resistance. CD163 + tumor-associated macrophages engaged non-regulatory T cells through GAL9–TIM-3 interactions, nominating TIM-3 blockade as a therapeutic strategy for mucosal melanoma. These findings define the distinct aggressive biology of mucosal melanoma and highlight potential therapeutic targets and mechanisms of immune resistance.
- Open Access
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8732
Author Correction: Specific oncogene activation of the cell of origin in mucosal melanoma
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8732
Open AccessAuthor Correction: Specific oncogene activation of the cell of origin in mucosal melanoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S5: Survival by ERBB2 status.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S5: Survival by ERBB2 status.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S1: Efficacy data of pembrolizumab and trebananib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S1: Efficacy data of pembrolizumab and trebananib.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S3: Tumor immune microenvironment of colorectal cancer cohort.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S3: Tumor immune microenvironment of colorectal cancer cohort.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S2: Treatment history of each patient with metastatic CRC with ERBB2 amplification and durable response to trial therapy in patient 32 (a) and patient 5 (b).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Supplementary Figure S2: Treatment history of each patient with metastatic CRC with ERBB2 amplification and durable response to trial therapy in patient 32 (a) and patient 5 (b).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
Table S3 from A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer